Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRO-SID
2019-004375-40Phase 3Terminated
- Sponsor
- Octapharma
- Start
- Feb 2020
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), secondary immunodeficiency (SID) and hypogammaglobulinemia comparing Panzyga prophylaxis with Placebo (2 arms). Primary endpoint: Occurrence of at least one major infection. Started Feb 2020; status: terminated.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)secondary immunodeficiency (SID)hypogammaglobulinemia
Beyond the preview
Go deeper on 2019-004375-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004375-40.